Status:

NOT_YET_RECRUITING

the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery

Lead Sponsor:

Xiangya Hospital of Central South University

Collaborating Sponsors:

Wu Jieping Medical Foundation

Conditions:

Acute Pain

Opioid Analgesic Adverse Reaction

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

The goal of this clinical trial is to learn if Oliceridine fumarate injection works to treat acute pain after abdominal surgery. It will also learn about the safety of Oliceridine fumarate injection. ...

Detailed Description

Traditional opioid, such as morphine, sufentanil , is an important drug treatment of postoperative period of acute pain, but their use is often limited because of significant side effects, such as res...

Eligibility Criteria

Inclusion

  • Preoperative inclusion criteria
  • aged ≥18 years and ≤75 years at screening;
  • Plan to undergo open or laparoscopic abdominal surgery, and the estimated operative time more than 2 hours.
  • able to understand and comply with research procedures and requirements, and can provide a written informed consent.
  • postoperative inclusion criteria:
  • patients who required open or laparoscopic surgery;
  • According to the investigator's judgment, the patient had recovered sufficiently from the intraoperative anesthesia protocol to accurately complete the protocol-specified questionnaire;

Exclusion

  • preoperative exclusion criteria:
  • ASA grade \>III
  • existing other acute or chronic pain conditions;
  • body mass index (BMI) \< 18 or \> 30 kg/m2;
  • with sleep apnea syndrome; 5 ) long-term opioid treatment, defined as receiving more than 15mg morphine equivalent units per day on more than 3 days per week for a period of more than 1 month in the 12 months prior to surgery;
  • 6\) suffering from mental or nervous system diseases (such as epilepsy, depression, schizophrenia, etc.), chronic obstructive pulmonary disease or pulmonary heart disease, heart failure, severe arrhythmia, etc; 7) with severe liver and kidney dysfunction; 8) Other conditions considered by the investigator to be inappropriate for enrollment.
  • Postoperative exclusion criteria:
  • intraoperative, postoperative or anesthetic deviations that may affect the efficacy and safety evaluation in the study;
  • evidence of hemodynamic instability or respiratory insufficiency.

Key Trial Info

Start Date :

August 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2026

Estimated Enrollment :

606 Patients enrolled

Trial Details

Trial ID

NCT06530563

Start Date

August 1 2025

End Date

May 1 2026

Last Update

August 19 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xiangya Hospital of Central South University

Changsha, Hunan, China, 410000